Fallopian Tube Cancer Trials

ORCCYD (ET743-OVC-3006): A Study Comparing the Combination of Trabectedin and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

• Women, ages 18 years or older, with advanced-relapsed ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

GOG 225: Can Diet and Physical Activity Modulate Ovarian and Primary Peritoneal Cancer Progression-Free Survival

• Women, ages 18 years or older, with confirmed ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call the Research Coordinator or visit the study weblink our Clinical Trials office at (910) 715-2200.

GOG 213: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

• Women, ages 18 years or older, with confirmed recurrent ovarian, fallopian tube, or primary peritoneal cancer. For additional criteria, call the Research Coordinator or visit the study weblink our Clinical Trials office at (910) 715-2200.

• Atrial Fibrillation
• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Venous Thromboembolism - Cancer Related
• Lymphomas
• Kidney Cancer
• Lung Cancer
• Multiple Myeloma
• Ovarian Cancer
• Peritoneal Cancer
• Prostate Cancer
• Solid Tumors